<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although the function and mechanism of action of long non-coding <z:chebi fb="40" ids="33697">RNAs</z:chebi> (lncRNA) is still not completely known, studies have shown their potential role in the control of gene expression and regulation, in cellular proliferation and invasiveness at the transcriptional level via multiple mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, <z:hpo ids='HP_0003003'>colon cancer</z:hpo> associated transcript 1 (CCAT1) lncRNA was found to be expressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> but not in <z:mpath ids='MPATH_458'>normal</z:mpath> tissue </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to study the ability of a CCAT1-specific <z:chebi fb="0" ids="48021">peptide nucleic acid</z:chebi> (<z:chebi fb="3" ids="48021">PNA</z:chebi>) based molecular beacons (TO-<z:chebi fb="3" ids="48021">PNA</z:chebi>-MB) to serve as a diagnostic probe for in vitro, ex vivo, and in situ (human colon biopsies) detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The data showed enhanced fluorescence upon in vitro hybridization to <z:chebi fb="40" ids="33697">RNA</z:chebi> extracted from CCAT1 expressing cells (HT-29, SW-480) compared to control cells (SK-Mel-2) </plain></SENT>
<SENT sid="4" pm="."><plain>Uptake of TO-<z:chebi fb="3" ids="48021">PNA</z:chebi>-MBs into cells was achieved by covalently attaching cell penetrating <z:chebi fb="7" ids="16670">peptides</z:chebi> (CPPs) to the TO-<z:chebi fb="3" ids="48021">PNA</z:chebi>-MB probes </plain></SENT>
<SENT sid="5" pm="."><plain>In situ hybridization of selected TO-<z:chebi fb="3" ids="48021">PNA</z:chebi>-MB in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> specimens was shown to detect CCAT1 expression in <z:hpo ids='HP_0000001'>all</z:hpo> (4/4) subjects with pre-cancerous <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and in <z:hpo ids='HP_0000001'>all</z:hpo> (8/8) patients with invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (penetrating the bowel wall) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The results showed that CCAT1 TO-<z:chebi fb="3" ids="48021">PNA</z:chebi>-MB is a powerful diagnostic tool for the specific identification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, suggesting that with the aid of an appropriate pharmaceutical vehicle, real time in vivo imaging is feasible </plain></SENT>
<SENT sid="7" pm="."><plain>TO-<z:chebi fb="3" ids="48021">PNA</z:chebi>-MB may enable identifying occult <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> during surgery, or differentiating in real time in vivo imaging, between benign and malignant lesions </plain></SENT>
</text></document>